FDA Clears Phase 2 Trial of Injectable PDGF for Under-Eye Hollows

The US FDA has cleared a Phase 2 clinical trial of injectable rhPDGF-BB for under-eye hollowing, according to Globalcosmeticsnews. The reported action advances clinical research involving a regenerative aesthetic treatment for this indication.

Phase 2 trial moves forward

Globalcosmeticsnews reported that the FDA cleared a Phase 2 study of injectable rhPDGF-BB for under-eye hollowing. The publication described the development as an advancement of clinical research into regenerative aesthetic treatments.

The FDA action reported by Globalcosmeticsnews applies to the clinical trial. The evidence identifies injectable rhPDGF-BB as the investigational treatment and under-eye hollowing as the focus of the study.

For professionals following pharmaceutical and biotech developments in aesthetic medicine, the event is a regulatory milestone for the research program. It places the injectable treatment in a Phase 2 clinical-trial setting.

What the reported action covers

Globalcosmeticsnews characterized the development as FDA clearance of a Phase 2 clinical trial. The report does not describe an FDA product approval for injectable rhPDGF-BB in under-eye hollowing.

That distinction is relevant when communicating about the development. The reported milestone concerns advancement of clinical research, rather than an approved treatment indication.

• Globalcosmeticsnews reported FDA clearance of a Phase 2 clinical trial.
• The investigational treatment is injectable rhPDGF-BB.
• The clinical-trial focus is under-eye hollowing.
• The research relates to regenerative aesthetic treatments.

Sales-facing context

For medical sales professionals working near regenerative aesthetics, the report provides a defined update: a Phase 2 trial has been cleared. Product, clinical, and commercial discussions can distinguish the reported study clearance from FDA approval of a treatment for under-eye hollowing.

Globalcosmeticsnews’ report centers on the trial’s progression and the continued study of injectable approaches within regenerative aesthetic research. The FDA clearance is the reported event, while the Phase 2 trial is the next identified clinical setting for injectable rhPDGF-BB.